AsiaIPEX is a one-stop-shop for players in the IP industry, facilitating IP trade and connection to the IP world. Whether you are a patent owner interested in selling your IP, or a manufacturer looking to buy technologies to upgrade your operation, you will find the portal a useful resource.

Back to search results

Novel Markers for the Treatment and Diagnosis of Chronic Lumphocytic Leukemia (CLL)

Technology Benefits

Technology can be used in the form of a kit for CLL diagnostics.Potential CLL therapy by inhibiting PDE7B, resulting in apoptosis of CLL lymphocytes.

Detailed Technology Description

Researchers at UC San Diego have developed a novel technology to diagnose CLL. They have demonstrated an enhanced expression of phosphodiesterase isoform 7B (PDE7B) in lymphocytes of CLL patients. Thus PDE7B can be used as a biomarker for diagnosis and prognosis of CLL.Features of this technology include: PDE7B mRNA and protein levels are increased in CLL patients to up to 70- and 90-fold, respectively.Potential therapeutic agents comprise PDE7B inhibitors, antagonists, and antibodies.

Supplementary Information

Patent Number: US7846664B2
Application Number: US200896628A
Inventor: Insel, Paul A. | Zhang, Lingzhi | Murray, Fiona | Kanter, Joan R. | Kipps, Thomas | Rassenti, Laura
Priority Date: 7 Dec 2005
Priority Number: US7846664B2
Application Date: 9 Jun 2008
Publication Date: 7 Dec 2010
IPC Current: C12Q000168 | C07H002102 | C07H002104
US Class: 43500612 | 435006 | 5360231 | 53602431 | 53602433
Assignee Applicant: The Regents of the University of California
Title: Diagnosis and treatment of chronic lymphocytic leukemia (CLL)
Usefulness: Diagnosis and treatment of chronic lymphocytic leukemia (CLL)
Summary: The method and kit are useful for diagnosing CLL. The method and composition are useful for treating CLL.
Novelty: Diagnosing chronic lymphocytic leukemia (CLL) comprises comparing the patient's expression level to the expression level of the isoform of PDE associated with CLL in a normal subject

Industry

Disease Diagnostic/Treatment

Sub Group

Cancer/Tumor

Application No.

7846664

Others

State Of Development

Increase in PDE7B levels has been detected in CLL patients.
This technology is offered exclusively or nonexclusively in the U.S.

Related Materials

Zhang, L., et al., Cyclic Nucleotide Phosphodiesterase Profiling Reveals Increased Expression of Phosphodiesterase 7B in Chronic Lymphocytic Leukemia. Proc Natl Acad Sci USA, 2008. 105(49): p. 19532-7.
News release at http://ucsdnews.ucsd.edu/newsrel/health/04-09AACR.asp
Zhang L, Murray F, Rassenti LZ, Pu M, Kelly C, Kanter JR, Greaves A, Messer K, Kipps TJ, Insel PA. Cyclic nucleotide phosphodiesterase 7B mRNA: an unfavorable characteristic in chronic lymphocytic leukemia. Int J Cancer. 2011 Sep 1;129(5):1162-9. doi: 10.1002/ijc.25785. Epub 2011 Feb 11.

Intellectual Property Info

Patent application (No. 12/960,955) allowance granted.

Tech ID/UC Case

19546/2006-052-0

Related Cases

2006-052-0

Country/Region

USA

For more information, please click Here